Detection of biomarker and development for new combination therapy for anti-EGFR monoclonal antibody cetuximab in lung cancer

Research Project

Project/Area Number	24790811
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Respiratory organ internal medicine
Research Institution	Tottori University
Principal Investigator	TAKATA Miyako 鳥取大学, 医学部, 研究員 (50523643)
Project Period (FY)	2012-04-01 – 2014-03-31
Project Status	Completed (Fiscal Year 2013)
Budget Amount *help	¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000) Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000) Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	非閉塞性肺疾患癌 / 分子標的治療
Research Abstract	This study is basic research that explore the biomarker and factors overcoming drug resistance to anti-EGFR monoclonal antibody cetuximab in lung cancer. We found that KREMEN1 gene was overexpressed and Wnt signaling pathway was highly activated in cetuximab resistant cells. Therefore the inhibition of Wnt signaling pathway can possibility overcome the acquired resistance for cetuximab. Moreover this results can be applicable for lung cancer that is inherently resistance for cetuximab.

Report

(3 results)